{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-24-000081","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.481428+00:00","generated_at":"2026-06-02T09:40:33.174741+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cartesian Q1 2024 net loss $56.8M; cash $104.8M; MG Phase 2b data on track for mid-2024","bullets":["Net loss $56.8M ($10.50/shr) vs $21.7M ($4.24/shr) Q1 2023; loss widened on higher G&A from merger.","Cash, equivalents, restricted cash $104.8M; expected to fund operations into 2H 2026.","R&D expenses $9.7M (down from $18.6M) on pipeline reprioritization; G&A $9.5M (up from $5.7M) on merger costs.","Phase 2b topline for Descartes-08 in myasthenia gravis expected mid-2024; SLE Phase 2 dosing starts Q2 2024.","Completed 1-for-30 reverse stock split and preferred conversion; new Maryland HQ expanding manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-24-000081","json":"https://secwatch.observer/filing/0001453687-24-000081.json","markdown":"https://secwatch.observer/filing/0001453687-24-000081.md","text":"https://secwatch.observer/filing/0001453687-24-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000081/0001453687-24-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000081/rnac-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:40:33.174741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f99e164de4e33f6d5a556987d9d30b51a39306db","claim":"Cartesian Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Cartesian Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000081/0001453687-24-000081-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}